William Blair lowered their Q3 2025 EPS estimates for ResMed in a research report issued on Monday, February 3rd. William Blair analyst M. Andrew now anticipates that the medical equipment provider ...
Zacks.com on MSN17h
Here's Why You Should Retain Glaukos Stock in Your Portfolio NowGlaukos Corporation GKOS is well-poised for growth on the back of favorable clinical trial results and a robust product ...
ASX stocks capped off a wild week (losses early but steadying late) with a narrow fall. Under the surface, there was plenty ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback